Herbal Remedy Beats Pharmaceuticals for Lowering Diabetes Risk

Diabetes has become widespread, with millions diagnosed annually. Dr. Mitchell Katz highlighted the urgent need for effective preventive treatments in JAMA Internal Medicine. In China, Jinlida granules, a traditional herbal remedy, show promise in reducing diabetes risk. Yet, regulatory complexities hinder their approval and availability in the U.S.

The study in JAMA Internal Medicine revealed Jinlida’s efficacy in lowering diabetes risk among individuals with impaired glucose tolerance. Participants, aged 18 to 70, underwent a comprehensive lifestyle program alongside Jinlida or a placebo. Those taking Jinlida saw a 41% lower risk of diabetes onset.

Researchers noted this as the first study to explore the combined effects of traditional Chinese medicine (TCM) and lifestyle adjustments for diabetes prevention. Jinlida users also experienced improvements in waist size, BMI, cholesterol, and blood sugar levels, including HbA1c.

While previous research supports Jinlida’s benefits for managing blood glucose, its adoption in the U.S. faces hurdles due to differing regulatory standards for herbal supplements and medications. Unlike pharmaceuticals, herbal supplements like Jinlida are classified as foods by the FDA, with less stringent premarket approval requirements.

Dr. Katz emphasized that despite positive trial results, herbal treatments like Jinlida face steep barriers in gaining FDA approval, such as demonstrating consistent composition and safety. These challenges are compounded by high approval costs, limiting access to potentially beneficial treatments.